Influence of Beta-cyclodextrin complexation on lovastatin release from osmotic pump tablets[OPT]

An extended-release osmotic dosage form was designed and the effect of beta-cyclodextrin [BCD] inclusion complexation on the solubility of lovastatin in aqueous media was investigated. The lovastatin BCD solid systems were prepared by kneading method. The elementary osmotic pumps [EOPs] were prepared with lovastatin BCD complex with cellulose acetate [CA] and polyethylene glycol as plasticizer. The effect of the BCD molar ratio on enhancement of lovastatin dissolution rate and the influences of various parameters [e.g. drug -BCD ratio, molecular weight and amount of PVP, coating weight gain] on drug release profiles were investigated. The solubility and dissolution rates of lovastatin were significantly increased by using inclusion complexation. It was found that PVP K90 was a suitable hydrophilic polymer with thickening effect and had profoundly positive effect on drug release. The present results confirmed that dissolution rate of lovastatin BCD were greatly enhanced and this system has suitable solubility behavior in EOP tablet formulations

Pharmacokinetic study on lovastatin sustained-release tablet and sustained-release capsule in Beagal dogs / 华中科技大学学报（医学）（英德文版）

This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet, Tp; sustained-release capsule, TJ and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. Tmax, Cmax and MRT revealed significant difference (P0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h.

EUM: Manejo de dislipidemias con gemfibrozilo, lovastatina y colestiramina tras seis años de protocolización terapéutica / EUM: Management of the dyslipidemias with Gemfibrozil, Lovastatin and Cholestyramine, later of six years of therapeutic protocolization

Con el fin de evaluar el uso racional de gemfibrozilo, lovastatina y colestiramina, se llevó a cabo un estudio de utilización de medicamentos por vía prescripción-indicación referido al protocolo Institucional sobre el manejo de las dislipidemias con medicamentos tras un período de dieta. El criterio fundamental para valorar la racionalidad de la indicación fue gemfibrozilo para hipertrigliceridemia pura o hiperlipidemia mixta, y colestiramina o lovastatina para hipercolesterolemia pura, a partir de las boletas del protocolo de tratamiento recibidas en el curso de 12 meses. El análisis incluyó n=3539 casos, y mostró el uso racional de los fármacos hipolipidemiantes en más del 87 por ciento de las prescripciones registradas; el uso irracional mostró diversas causas. Se incluye que existe un predominante uso racional de hipolipidemiantes y que la protocolización terapéutica tuvo un impacto positivo en el perfil de prescripción.